Literature DB >> 21872626

Mismatches outside exons 2 and 3 do not alter the peptide motif of the allele group B*44:02P.

Christina Bade-Doeding1, Pedro Cano, Trevor Huyton, Soumya Badrinath, Britta Eiz-Vesper, Oliver Hiller, Rainer Blasczyk.   

Abstract

Sequence variations outside exons 2 and 3 do not appear to affect the function of human leukocyte antigen (HLA) class I alleles. HLA-B*44:02:01:01 and -B*44:27 are considered functionally identical because they differ by a single amino acid substitution of Val > Ala at position 199, which is located in the α3 domain. To validate that HLA-B*44:02:01:01 and -B*44:27 represent functionally identical alleles that might reflect a permissive mismatch in hematopoetic stem cell transplantation (HSCT), we determined their peptide-binding features. B-lymphoblastic cells were lentivirally transduced with B*44:02 and B*44:27 constructs and soluble recombinant molecules were purified by affinity chromatography. Peptides were isolated and sequencing of single peptides was performed using liquid chromatography-electrospray ionization-tandem mass spectrometry (LTQ-Orbitrap) technology. We demonstrate that the peptide motif of B*44:02(199Val) and B*44:27(199Ala) is identical. Both variants feature E at P2 and Y, F, or W at PΩ in their ligands. Most of the identified peptides are 9 to 11 amino acids in length and approximately 20% of these ligands are shared between the alleles. Our results lead to the conclusion that B*44:02:01:01 and B*44:27 might have the same immune function, validating a theory that is now being used in deciding which donors to select in HSCT when there is no identical donor available.
Copyright © 2011 American Society for Histocompatibility and Immunogenetics. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21872626     DOI: 10.1016/j.humimm.2011.08.004

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  14 in total

1.  Position 45 influences the peptide binding motif of HLA-B*44:08.

Authors:  Soumya Badrinath; Trevor Huyton; Heike Schumacher; Rainer Blasczyk; Christina Bade-Doeding
Journal:  Immunogenetics       Date:  2011-10-19       Impact factor: 2.846

2.  Residue 81 confers a restricted C-terminal peptide binding motif in HLA-B*44:09.

Authors:  Trevor Huyton; Heike Schumacher; Rainer Blasczyk; Christina Bade-Doeding
Journal:  Immunogenetics       Date:  2012-06-16       Impact factor: 2.846

3.  The human leukocyte antigen-presented ligandome of B lymphocytes.

Authors:  Chopie Hassan; Michel G D Kester; Arnoud H de Ru; Pleun Hombrink; Jan Wouter Drijfhout; Harm Nijveen; Jack A M Leunissen; Mirjam H M Heemskerk; J H Frederik Falkenburg; Peter A van Veelen
Journal:  Mol Cell Proteomics       Date:  2013-03-12       Impact factor: 5.911

4.  Limited HLA sequence variation outside of antigen recognition domain exons of 360 10 of 10 matched unrelated hematopoietic stem cell transplant donor-recipient pairs.

Authors:  L Hou; C Vierra-Green; A Lazaro; C Brady; M Haagenson; S Spellman; C K Hurley
Journal:  HLA       Date:  2016-12-15       Impact factor: 4.513

5.  Soluble HLA technology as a strategy to evaluate the impact of HLA mismatches.

Authors:  Heike Kunze-Schumacher; Rainer Blasczyk; Christina Bade-Doeding
Journal:  J Immunol Res       Date:  2014-09-01       Impact factor: 4.818

6.  Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes.

Authors:  Maren Bieling; Sabine Tischer; Ulrich Kalinke; Rainer Blasczyk; Søren Buus; Britta Maecker-Kolhoff; Britta Eiz-Vesper
Journal:  Oncotarget       Date:  2017-12-21

7.  NKG2A/CD94 Is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain.

Authors:  Gia-Gia T Hò; Alexander A Celik; Trevor Huyton; Wiebke Hiemisch; Rainer Blasczyk; Gwendolin S Simper; Christina Bade-Doeding
Journal:  Int J Mol Sci       Date:  2020-06-19       Impact factor: 5.923

8.  HLA-E: Presentation of a Broader Peptide Repertoire Impacts the Cellular Immune Response-Implications on HSCT Outcome.

Authors:  Thomas Kraemer; Alexander A Celik; Trevor Huyton; Heike Kunze-Schumacher; Rainer Blasczyk; Christina Bade-Döding
Journal:  Stem Cells Int       Date:  2015-08-12       Impact factor: 5.443

9.  Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02.

Authors:  Gwendolin S Simper; Gia-Gia T Hò; Alexander A Celik; Trevor Huyton; Joachim Kuhn; Heike Kunze-Schumacher; Rainer Blasczyk; Christina Bade-Döding
Journal:  J Immunol Res       Date:  2018-09-13       Impact factor: 4.818

10.  HLA-G peptide preferences change in transformed cells: impact on the binding motif.

Authors:  Alexander A Celik; Gwendolin S Simper; Wiebke Hiemisch; Rainer Blasczyk; Christina Bade-Döding
Journal:  Immunogenetics       Date:  2018-03-30       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.